| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 828.80 | 7.6% |
| Total Income | 828.80 | 7.6% |
| Expenditure | 817.84 | 8.0% |
| PBT | 10.96 | 18.6% |
| Net Profit | 4.11 | 50.9% |
| OPM | — | |
| NPM | 0.49% | 0.59pp |
| EPS | 0.05 | 44.4% |
Acadia Healthcare Reports Q1 2026 Revenue Up 7.6% to $828.8 Million
03 May 2026 · 3 May, 6:22 pm
Summary
Acadia Healthcare announced its first quarter 2026 financial results, reporting a 7.6% increase in revenue to $828.8 million. Same-facility revenue grew by 7.3%, driven by increases in both revenue per patient day and patient days. Adjusted EBITDA increased to $144.2 million from $134.2 million in the prior-year period. The company is raising its full year 2026 Adjusted EBITDA and Adjusted EPS guidance. Debbie Osteen, Chief Executive Officer, expressed satisfaction with the company's performance and focus on sustained performance and long-term value.
Key Highlights
- 1
Acadia Healthcare's revenue totaled $828.8 million, a 7.6% increase compared to the first quarter of 2025.
- 2
Same-facility revenue increased by 7.3% compared to the first quarter of 2025, driven by a 5.6% increase in revenue per patient day and a 1.6% increase in patient days.
- 3
Adjusted EBITDA was $144.2 million, compared to $134.2 million in the prior-year period.
- 4
The company added 82 newly licensed beds during the first quarter, including 42 beds to existing facilities and 40 beds from newly constructed facilities.
- 5
Acute inpatient psychiatric facility revenue increased by 14% over the prior year’s first quarter, reaching $470.7 million.
- 6
The company is increasing its full year 2026 Adjusted EBITDA guidance to $580 to $615 million and Adjusted EPS guidance to $1.35 to $1.60.
- 7
Residential treatment facility revenue increased by 6.3% to $89.6 million compared to the prior year’s first quarter.
Management Comments
Debbie Osteen
“The good start to the year reflects disciplined execution throughout Acadia as we provide quality care for individuals seeking treatment for mental health and substance abuse issues." “Strong patient volumes across our Acute and RTC businesses, along with continued operating efficiencies across the Company, enabled us to exceed the high end of our Adjusted EBITDA guidance. I am very pleased with how the team has responded in my first few months back as CEO, and we are building on this progress with a clear focus on sustained performance and long‑term value.”
Informational and educational content only. Not investment advice.